A distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia
Pathogen clearance and resolution of inflammation in patients with pneumonia require an effective local T cell response. Nevertheless, local T cell activation may drive lung injury, particularly during prolonged episodes of respiratory failure characteristic of severe SARS-CoV-2 pneumonia. While T cell responses in the peripheral blood are well described, the evolution of T cell phenotypes and molecular signatures in the distal lung of patients with severe pneumonia caused by SARS-CoV-2 or other pathogens is understudied. Accordingly, we serially obtained 432 bronchoalveolar lavage fluid samples from 273 patients with severe pneumonia and respiratory failure, including 74 unvaccinated patients with COVID-19, and performed flow cytometry, transcriptional, and T cell receptor profiling on sorted CD8+ and CD4+ T cell subsets. In patients with COVID-19 but not pneumonia secondary to other pathogens, we found that early and persistent enrichment in CD8+ and CD4+ T cell subsets correlated with survival to hospital discharge. Activation of interferon signaling pathways early after intubation for COVID-19 was associated with favorable outcomes, while activation of NF-κB-driven programs late in disease was associated with poor outcomes. Patients with SARS-CoV-2 pneumonia whose alveolar T cells preferentially targeted the Spike and Nucleocapsid proteins tended to experience more favorable outcomes than patients whose T cells predominantly targeted the ORF1ab polyprotein complex. These results suggest that in patients with severe SARS-CoV-2 pneumonia, alveolar T cell interferon responses targeting structural SARS-CoV-2 proteins characterize patients who recover, yet these responses progress to NF-κB activation against non-structural proteins in patients who go on to experience poor clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 14. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Markov, Nikolay S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.12.13.571479 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366589768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366589768 | ||
| 003 | DE-627 | ||
| 005 | 20240210233040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.13.571479 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM366589768 | ||
| 035 | |a (NLM)38168346 | ||
| 035 | |a (PII)2023.12.13.571479 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Markov, Nikolay S |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Pathogen clearance and resolution of inflammation in patients with pneumonia require an effective local T cell response. Nevertheless, local T cell activation may drive lung injury, particularly during prolonged episodes of respiratory failure characteristic of severe SARS-CoV-2 pneumonia. While T cell responses in the peripheral blood are well described, the evolution of T cell phenotypes and molecular signatures in the distal lung of patients with severe pneumonia caused by SARS-CoV-2 or other pathogens is understudied. Accordingly, we serially obtained 432 bronchoalveolar lavage fluid samples from 273 patients with severe pneumonia and respiratory failure, including 74 unvaccinated patients with COVID-19, and performed flow cytometry, transcriptional, and T cell receptor profiling on sorted CD8+ and CD4+ T cell subsets. In patients with COVID-19 but not pneumonia secondary to other pathogens, we found that early and persistent enrichment in CD8+ and CD4+ T cell subsets correlated with survival to hospital discharge. Activation of interferon signaling pathways early after intubation for COVID-19 was associated with favorable outcomes, while activation of NF-κB-driven programs late in disease was associated with poor outcomes. Patients with SARS-CoV-2 pneumonia whose alveolar T cells preferentially targeted the Spike and Nucleocapsid proteins tended to experience more favorable outcomes than patients whose T cells predominantly targeted the ORF1ab polyprotein complex. These results suggest that in patients with severe SARS-CoV-2 pneumonia, alveolar T cell interferon responses targeting structural SARS-CoV-2 proteins characterize patients who recover, yet these responses progress to NF-κB activation against non-structural proteins in patients who go on to experience poor clinical outcomes | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Ren, Ziyou |e verfasserin |4 aut | |
| 700 | 1 | |a Senkow, Karolina J |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Rogan A |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Malsin, Elizabeth S |e verfasserin |4 aut | |
| 700 | 1 | |a Sichizya, Lango |e verfasserin |4 aut | |
| 700 | 1 | |a Kihshen, Hermon |e verfasserin |4 aut | |
| 700 | 1 | |a Helmin, Kathryn A |e verfasserin |4 aut | |
| 700 | 1 | |a Jovisic, Milica |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Jason M |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Leonor, Xóchitl G |e verfasserin |4 aut | |
| 700 | 1 | |a Abdala-Valencia, Hiam |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminathan, Suchitra |e verfasserin |4 aut | |
| 700 | 1 | |a Nwaezeapu, Julu |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Mengjia |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmussen, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Ozer, Egon A |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo-Redondo, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Hultquist, Judd F |e verfasserin |4 aut | |
| 700 | 1 | |a Simons, Lacy M |e verfasserin |4 aut | |
| 700 | 1 | |a Rios-Guzman, Estefany |e verfasserin |4 aut | |
| 700 | 1 | |a Misharin, Alexander V |e verfasserin |4 aut | |
| 700 | 1 | |a Wunderink, Richard G |e verfasserin |4 aut | |
| 700 | 1 | |a Budinger, G R Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Benjamin D |e verfasserin |4 aut | |
| 700 | 1 | |a Morales-Nebreda, Luisa |e verfasserin |4 aut | |
| 700 | 0 | |a NU SCRIPT Study Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 14. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.13.571479 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 12 | ||